CardiologyOnline.net

Cardiology Xagena

Xagena Mappa
Medical Meeting
Mediexplorer.it
Xagena Salute

Search results for "Non-valvular atrial fibrillation"

The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product Xarelto ( Riva ...


The four-year follow-up data from the PROTECT AF clinical trial demonstrated the Watchman Left Atrial Appendage ( LAA ) Closure device was statistically superior to Warfarin ( Coumadin ) for preventin ...


Anticoagulant treatment with vitamin K antagonists ( VKAs ) is aimed at preventing thromboembolic complications and has been the therapy of choice for most people with non-valvular atrial fibrillation ...


The comparative safety of Dabigatran ( Pradaxa ) versus Warfarin ( Coumadin ) for treatment of non-valvular atrial fibrillation in general practice settings has not been established. Researchers fo ...


European Xarelto ( Rivaroxaban ) product information has now included guidance for use in patients with atrial fibrillation undergoing cardioversion. The label update is based on findings from the ...


The aim of a study was to evaluate the population pharmacokinetics ( PK ) and exposure-response relationship of Edoxaban ( Lixiana, Savaysa ) in patients with non-valvular atrial fibrillation ( AF ). ...


The recent availability of Dabigatran ( Pradaxa ), a novel oral anticoagulant, provided a new treatment option for stroke prevention in atrial fibrillation beyond Warfarin ( Coumadin ), the main thera ...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk of stroke for patients with non-valvular atrial fibrillation ( NVAF ) w ...


The European Society of Cardiology ( ESC ) has recommended uninterrupted anticoagulation with vitamin K antagonists during ablation and device implantation in a position paper presented at EHRA EUROPA ...


While bleeding is a well-known complication of Warfarin ( Coumadin ) use and is thought to be a contributory cause of treatment discontinuation, studies quantifying this association are limited. The ...


Apixaban ( Eliquis ), a direct factor Xa inhibitor approved for thromboembolic prophylaxis in patients with non-valvular atrial fibrillation, is increasingly used in patients undergoing catheter ablat ...


Results from the global phase 3b ENSURE-AF ( EdoxabaN vs warfarin in subjectS UndeRgoing cardiovErsion of AtrialFibrillation ) study of 2,199 patients with non-valvular atrial fibrillation ( NVAF ) un ...


In addition to Warfarin ( Coumadin ), there are four non-vitamin K antagonist oral anticoagulants ( NOACs ) available for stroke prevention in non-valvular atrial fibrillation ( NVAF ). There are li ...


Findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and rate of major bleeding among patients with non-valvular atrial fibrillation ...


The results from an independent retrospective comparative study, published in the American Journal of Medicine, have shown that Dabigatran was associated with a more favourable benefit-harm profile th ...